Tamoxifen Dose De-Escalation : An Effective Strategy for Reducing Adverse Effects?
© 2024. The Author(s)..
Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose of 20 mg daily presents challenges due to a broad spectrum of adverse effects, contributing to high discontinuation rates. Dose reductions of tamoxifen might be an option to reduce treatment-related toxicity, but large randomized controlled trials investigating the tolerability and, more importantly, efficacy of low-dose tamoxifen in the adjuvant setting are lacking. We conducted an extensive literature search to explore evidence on the tolerability and clinical efficacy of reduced doses of tamoxifen. In this review, we discuss two important topics regarding low-dose tamoxifen: (1) the incidence of adverse effects and quality of life among women using low-dose tamoxifen; and (2) the clinical efficacy of low-dose tamoxifen examined in the preventive setting and evaluated through the measurement of several efficacy derivatives. Moreover, practical tools for tamoxifen dose reductions in the adjuvant setting are provided and further research to establish optimal dosing strategies for individual patients are discussed.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Drugs - (2024) vom: 14. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Buijs, Sanne M [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 14.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1007/s40265-024-02010-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369703294 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM369703294 | ||
003 | DE-627 | ||
005 | 20240315000351.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40265-024-02010-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1329.xml |
035 | |a (DE-627)NLM369703294 | ||
035 | |a (NLM)38480629 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Buijs, Sanne M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tamoxifen Dose De-Escalation |b An Effective Strategy for Reducing Adverse Effects? |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 14.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024. The Author(s). | ||
520 | |a Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose of 20 mg daily presents challenges due to a broad spectrum of adverse effects, contributing to high discontinuation rates. Dose reductions of tamoxifen might be an option to reduce treatment-related toxicity, but large randomized controlled trials investigating the tolerability and, more importantly, efficacy of low-dose tamoxifen in the adjuvant setting are lacking. We conducted an extensive literature search to explore evidence on the tolerability and clinical efficacy of reduced doses of tamoxifen. In this review, we discuss two important topics regarding low-dose tamoxifen: (1) the incidence of adverse effects and quality of life among women using low-dose tamoxifen; and (2) the clinical efficacy of low-dose tamoxifen examined in the preventive setting and evaluated through the measurement of several efficacy derivatives. Moreover, practical tools for tamoxifen dose reductions in the adjuvant setting are provided and further research to establish optimal dosing strategies for individual patients are discussed | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Koolen, Stijn L W |e verfasserin |4 aut | |
700 | 1 | |a Mathijssen, Ron H J |e verfasserin |4 aut | |
700 | 1 | |a Jager, Agnes |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drugs |d 1976 |g (2024) vom: 14. März |w (DE-627)NLM00001611X |x 1179-1950 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:14 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40265-024-02010-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 14 |c 03 |